来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

交易中 07-07 13:35:38

7.190

-0.230

-3.10%

最高7.800	最低7.180	成交量105.05万
今开7.400	昨收7.420	日振幅8.36%
总市值32.28亿	流通市值32.28亿	总股本4.49亿
成交额777.19万	换手率0.23%	流通股本4.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":7.19,"timestamp":1783402532366,"preClose":7.42,"halted":0,"volume":1050500,"delay":0,"changeRate":-0.03099730458221018,"floatShares":449000000,"shares":449000000,"eps":-0.59,"marketStatus":"交易中","change":-0.23,"latestTime":"07-07 13:35:38","open":7.4,"high":7.8,"low":7.18,"amount":7771897,"amplitude":0.083558,"askPrice":7.2,"askSize":1500,"bidPrice":7.19,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.565,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1783411800000},"marketStatusCode":2,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":7.42,"openAndCloseTimeList":[[1783387800000,1783396800000],[1783400400000,1783411200000]],"volumeRatio":0.547067,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105/wiki","defaultTab":"wiki","newsList":[{"id":"1175908037","title":"来凯医药-B6月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1175908037","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175908037?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:12","pubTimestamp":1783069928,"startTime":"0","endTime":"0","summary":"来凱醫藥有限公司2026年6月股份变动月报表于2026年7月3日发布，报告期截至2026年6月30日。公告显示，公司法定/注册股本均未发生变化，截至报告期末，法定/注册股本总额为50,000美元，股本数量维持5,000,000,000股，面值为每股0.00001美元。在已发行股份方面，本月未有新增发行或股份变动。公司“2024年股份奖励计划”在报告期内亦无新股或库存股份变动。本月内，公司未进行任何股份购回及注销，股本总数相较上月保持不变。本公告由公司秘书柯晨煜签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648728665","title":"港股异动 | 来凯医药-B(02105.HK)涨超7% 拟回购股份及高管拟增持股份 涉资最多5600万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648728665","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648728665?lang=zh_cn&edition=full","pubTime":"2026-07-02 14:56","pubTimestamp":1782975368,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648527295","title":"来凯医药-B(02105.HK)启动场内回购及管理层拟同步增持，合计最高斥资5600万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648527295","media":"中金财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648527295?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:27","pubTimestamp":1782952024,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨来凯医药-B(02105.HK)发布公告，为彰显对公司业务前景的信心，并为股东创造价值，董事会于2026年7月1日批准，根据回购授权，在公开市场上购回股份。与此同时，董事会获悉，公司董事会主席吕向阳连同公司若干高级管理层成员，拟透过在公开市场上购买公司股份，以增持其于公司的股权。场内股份回购计划将以公司现有的可用现金资源拨付。公司其后将购回的股份注销。高级管理层增持股份计划将以其个人财务资源拨付。\r\n\r\n　　上述同步行动反映董事会及管理层对公司业务前景及未来发展充满信心，并将有利于公司及为股东创造价值。公司进行场内股份回购及高级管理层增持股份的合计金额最多为港币5600万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260702/32296702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377991","title":"来凯医药-B(02105)：柯晨煜担任公司秘书的资格获联交所确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377991","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647377991?lang=zh_cn&edition=full","pubTime":"2026-06-29 22:00","pubTimestamp":1782741658,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，联交所已确认柯晨煜先生符合上市规则第3.28条及第8.17条下担任本公司公司秘书的资格。本公司其中一名联席公司秘书何咏雅女士已提呈辞任本公司联席公司秘书及上市规则下的本公司授权代表，自2026年6月29日起生效。同时，何女士根据香港法例第622章《公司条例》第16部作为本公司授权代表，代本公司于香港接收法律程序文件及通知的持续角色维持不变。何女士辞任联席公司秘书后，柯先生将继续留任，并担任本公司的唯一公司秘书。柯先生亦已获委任为上市规则第3.05条下的本公司授权代表，自2026年6月29日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"us","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["03690","00780","09678","09880","06979","02553","09878","002352","000951","02279","01384","02526","07688","02555","300364","00917","02511","300760","00600","01024","09992","02105","09959","02687","002600","01952","02273","002714","01497","001248","02408","02643","01768","02170","02718","01833","02729","01021","000039","01951","06963","01519","002779","06668","02661","02590","000338","002594","02121","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340125","title":"港股异动 | 来凯医药-B(02105.HK)午前涨近15% 有关LAE118独家许可协议取得新进展 已收到Vasque Bio首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340125","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647340125?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:53","pubTimestamp":1782705189,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647419693","title":"替尔泊肽借力来凯医药-B(02105)LAE102联用，推动增肌减脂“中国方案”创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2647419693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647419693?lang=zh_cn&edition=full","pubTime":"2026-06-29 08:32","pubTimestamp":1782693155,"startTime":"0","endTime":"0","summary":"近年来，“增肌减脂”概念逐渐成为千亿减重市场新热门。而在“增肌减脂”方向，来凯医药-B自主研发的LAE102与礼来Bimagrumab是这一赛道的先行者。LAE102是全球范围内除了Bimagrumab之外，为数不多的已经进入临床试验阶段的靶向ActRII的在研品种。本次IIT通过LAE102与替尔泊肽联合使用，有望探索新一代联合疗法使肥胖患者获得更有效的长期获益，在“增肌减脂”这个巨大、潜在的未满足需求上推动“中国方案”的持续创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645868446","title":"来凯医药(2105.HK)PI3Kα抑制剂授权出海 已收到合作伙伴Vasque Bio首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2645868446","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645868446?lang=zh_cn&edition=full","pubTime":"2026-06-24 08:57","pubTimestamp":1782262621,"startTime":"0","endTime":"0","summary":"2026年6月24日——来凯医药宣布：来凯与Vasque Bio 6月9日签订的有关LAE118独家许可协议取得新进展：集团已根据许可协议，收到了Vasque Bio的首付款，包括1000万美元现金以及一项权益——即无需额外对价的情况下，有权获得Vasque Bio 已发行普通股最多达高双位数百分比的股权，或替代该等普通股的现金付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260624/32287844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644719112","title":"【券商聚焦】国泰海通维持来凯医药-B(02105)“增持”评级 看好与Vasque签订的LAE118独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2644719112","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644719112?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:55","pubTimestamp":1781682934,"startTime":"0","endTime":"0","summary":"维持“增持”评级，给予目标价14.15港元。研报核心关注点在于来凯医药与Vasque Bio签订的LAE118独家许可协议。根据协议，来凯医药有权获得1000万美元首付款、Vasque Bio最高达高双位数百分比的普通股股权、总额最高达5.17亿美元的里程碑付款，以及许可区域内净销售额个位数至双位数百分比的梯度销售分成。若Vasque Bio达成符合特定条件的战略合作或收购交易，来凯医药还可获得最高达该交易价值50%的额外付款。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984001","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02611","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642072259","title":"港股异动 | 来凯医药-B(02105)涨超5% 近日就LAE118与Vasque Bio签订全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2642072259","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642072259?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:37","pubTimestamp":1781235478,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药-B发布公告，于2026年6月9日，本集团与Vasque Bio,Inc.签订了一项独家许可协议。作为回报，本集团有权获得一笔不可退还且不可抵扣的首付现金款项1000万美元，以及在无需额外对价的情况下，有权获得Vasque Bio已发行普通股最多达高双位数百分比的股权，或替代该等普通股的现金付款。如Vasque Bio达成符合特定条件的合格战略合作或收购交易，本集团将有权获得额外付款，金额最高可达该战略交易价值的50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","02105","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642047201","title":"5.27亿美元！来凯医药（02105）黄金靶点，站上NewCo 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2642047201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642047201?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:37","pubTimestamp":1781138277,"startTime":"0","endTime":"0","summary":"康诺亚CM3362024年以NewCo交易出海，首付款仅1600万美元，但NewCo公司今年被吉利德以21.75亿美元收购，康诺亚斩获2.57亿美元首付款。来凯LAE118出海首付款为1000万美元，但Vasque Bio后续若被收购，来凯分成比例最高达50%。作为经典的黄金靶点，PI3Kα仍在赶赴大药之旅。诺华Alpelisib自2019年获批上市以来，销售峰值止步于5亿美元级别。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["DULL","PALL","GDXY","SHNY","GBUG","MGCmain","IAU","XME","BTGD","159934","GLD","GLDM","02105","1OZmain","DGP","GDX","SGDM","QOmain","SGCmain","PICK","DUST","159831","FGDL","GDXD","DBC","GCmain","GLL","IAUM","OUNZ","NUGT","UYM","GDXJ","JNUG","SGOL","CEF","DZZ","BAR","JDST","GDXU","USG","PHYS","GOLY","RING","BEGS","IAUI","AAAU","UGL","GOAU","SGUmain","GLTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642641910","title":"1000万美元首付+5.17亿美元里程碑付款：来凯医药-B达成海外授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2642641910","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642641910?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:31","pubTimestamp":1781055060,"startTime":"0","endTime":"0","summary":"6月10日，来凯医药-B（02105）发布公告，公司与VasqueBio,Inc.签订了一项独家许可协议，涉及其自主研发的新型PI3Kα泛突变选择性抑制剂LAE118。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766021358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642041563","title":"来凯医药-B(02105)与VASQUE BIO就LAE118签订中国以外地区的独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2642041563","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642041563?lang=zh_cn&edition=full","pubTime":"2026-06-10 08:15","pubTimestamp":1781050552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，于2026年6月9日，本集团与Vasque Bio,Inc.签订了一项独家许可协议。董事会认为，该许可协议的签订符合本公司及其股东的整体最佳利益。Vasque Bio主要专注于罕见疾病治疗药物的开发，本集团则专注于在授权区域以外开发LAE118的肿瘤疗法。获得Vasque Bio已发行普通股的权利，亦使本集团能够保留LAE118未来的增值潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BIO","BK1161","LU1169589451.USD","BK4588","BK4121","02105","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142079456","title":"来凯医药-B更新5月股份变动月报表，已发行普通股增至449,331,350股","url":"https://stock-news.laohu8.com/highlight/detail?id=1142079456","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142079456?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:06","pubTimestamp":1780563992,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年6月4日公布截至2026年5月31日的股份变动月报表。本月报显示，公司注册股本未发生变动，仍为5,000,000,000股普通股，面值每股0.00001美元，总注册股本50,000美元。报告期内，公司已发行股本由原先的446,466,350股增加至449,331,350股，新增发行2,865,000股普通股。公司本月无股份购回或注销活动，库藏股余额保持为0股。期末普通股股本总数变动为449,331,350股。本次公告由来凯医药有限公司联席公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138972669","title":"来凯医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1138972669","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138972669?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:56","pubTimestamp":1778770575,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于5月14日发布公告，董事会建议于6月5日举行的股东周年大会上，寻求一般授权回购不超过公司于决议案通过当日已发行股本的10%。截至最后可行日期，公司已发行股份总数约为449,331,350股，若该授权获股东会议通过且在此期间无新增发行或回购，公司可回购的股份数量最高可达44,933,135股。公司股东周年大会订于2026年6月5日召开，并将于2026年6月2日至2026年6月5日暂时停止办理股份过户登记，股东及投资者可关注相关日程安排。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761328","title":"港股异动 | 来凯医药-B(02105)午前涨超5% LAE002 III期临床到达终点 将提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761328","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635761328?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:58","pubTimestamp":1778731118,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药核心产品AKT抑制剂LAE002治疗乳腺癌的III期临床试验已于4月15日宣布达到主要终点。根据公司计划，将协同合作伙伴齐鲁制药于近期向国家药监局提交新药上市申请。齐鲁制药也于4月30日宣布将推进该药的国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4588","BK1161","02105","BK4585","BK4134","VXUS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635243220","title":"MSCI全球小盘股指数5月调整：美图公司(01357)等14只股票获纳入 剑桥科技(06166)等21只被剔除","url":"https://stock-news.laohu8.com/highlight/detail?id=2635243220","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635243220?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:01","pubTimestamp":1778637673,"startTime":"0","endTime":"0","summary":"此外，MSCI全球小盘股指数于中国香港地区纳入来凯医药、美华创富、珩湾科技，同时剔除百富环球、数码通电讯。纳入或剔除MSCI全球小盘股指数意味着股票将被全球主流机构投资者重点关注或移出其投资组合，直接影响公司的国际资本关注度、资金流向与市场流动性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765059.SGD","BK0214","SRTY","LU2045819591.USD","BK1609","LU1691799644.USD","BK4112","BK1095","603083","00357","BK1615","01515","LU0082770016.SGD","LU0231459107.USD","LU0278937759.USD","01523","00315","LU2125910500.SGD","LU2265009873.SGD","LU2210149790.SGD","002936","06166","MSCI","MNQmain","LU0175139822.USD","LU2095319765.USD","01357","LU0620787316.HKD","IE0009570106.USD","BK1618","LU1804176565.USD","BK4585","LU0289739343.SGD","09985","LU0511384066.AUD","02105","BK1613","LU1267930730.SGD","RWM","00327","RSSL","BK4550","06196","LU0672654240.SGD","BK1128","IWN","LU2210150020.SGD","BK1149","LU0164939612.USD","LU0390134368.USD","LU2125910849.SGD","LU0289961442.SGD","00347","MGRT","IWMI","BK1612","IWF","BK4581","09899","LU0082770016.USD","000898","UWM","AVUV","BK1240","00772","RYLD","VTWO","TWM","BK4535","LU0289960550.SGD","02373","BK4534","VB","BK4588","LU0708995401.HKD","IE00BKPKM429.USD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634408851","title":"港股异动 | 来凯医药-B(02105)午后涨超10% 齐鲁制药推进LAE002上市申请 公司有望获首付款及里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2634408851","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634408851?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:32","pubTimestamp":1778481147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B午后涨超10%，截至发稿，涨9.63%，报14.8港元，成交额6089.13万港元。4月30日，齐鲁制药官方宣布，由其独家引进中国区域研发与商业化权益的创新靶向药afuresertib临床研究达到主要终点，齐鲁制药独家引进推进国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK4585","BK1161","01477","IPOS","VXUS","BK1191","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634422784","title":"来凯医药-B(02105)发行合共286.5万股以满足根据2024年股份奖励计划授予的RSU的归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2634422784","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634422784?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:06","pubTimestamp":1778458011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年5月8日，该公司发行合共286.5万股普通股以满足根据2024年股份奖励计划授予的RSU的归属。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147680970","title":"来凯医药-B：根据2024年股份奖励计划发行2,865,000股新股，已发行股本增至449,331,350股","url":"https://stock-news.laohu8.com/highlight/detail?id=1147680970","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147680970?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:02","pubTimestamp":1778457723,"startTime":"0","endTime":"0","summary":"来凯医药有限公司（股票代码：02105）于2026年5月11日发布公告称，公司于2026年5月8日分别发行普通股1,200,000股和1,665,000股，合计2,865,000股，全部用于满足依据2024年股份奖励计划授予的限制性股票单位（RSU）归属。两次发行分别占变动前已发行股本的约0.2688%和0.3729%，合计占变动前已发行股本的约0.64%，发行价格均为每股0港元。\n本次股份发行完成后，公司已发行股本由原先的446,466,350股增加至449,331,350股。公司确认已遵守包括香港联合交易所有限公司证券上市规则在内的所有适用法律及监管规定。该公告由联席公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B：根据2024年股份奖励计划发行2,865,000股新股，已发行股本增至449,331,350股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.0646},{"period":"1month","weight":-0.255},{"period":"3month","weight":-0.5552},{"period":"6month","weight":-0.4646},{"period":"1year","weight":-0.5716},{"period":"ytd","weight":-0.4532}],"compareEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0597},{"period":"6month","weight":-0.1074},{"period":"1year","weight":-0.0125},{"period":"ytd","weight":-0.0786}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.226423},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021549},{"month":8,"riseRate":0.666667,"avgChangeRate":0.069227},{"month":9,"riseRate":0.666667,"avgChangeRate":0.04052},{"month":10,"riseRate":0.666667,"avgChangeRate":0.10793},{"month":11,"riseRate":1,"avgChangeRate":0.401946},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}